Bank Julius Baer & Co. Ltd Zurich Has $192,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Bank Julius Baer & Co. Ltd Zurich lessened its stake in Eli Lilly and Company (NYSE:LLY) by 65.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 1,137 shares of the company’s stock after selling 2,131 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Eli Lilly and were worth $192,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Moody Lynn & Lieberson LLC increased its stake in shares of Eli Lilly and by 16.3% during the 4th quarter. Moody Lynn & Lieberson LLC now owns 98,229 shares of the company’s stock worth $16,585,000 after purchasing an additional 13,739 shares during the last quarter. Toronto Dominion Bank increased its stake in shares of Eli Lilly and by 11.8% during the 4th quarter. Toronto Dominion Bank now owns 553,515 shares of the company’s stock worth $93,454,000 after purchasing an additional 58,220 shares during the last quarter. Steel Peak Wealth Management LLC increased its stake in shares of Eli Lilly and by 60.1% during the 4th quarter. Steel Peak Wealth Management LLC now owns 6,188 shares of the company’s stock worth $1,045,000 after purchasing an additional 2,323 shares during the last quarter. Redpoint Investment Management Pty Ltd increased its stake in shares of Eli Lilly and by 7.9% during the 4th quarter. Redpoint Investment Management Pty Ltd now owns 22,978 shares of the company’s stock worth $3,880,000 after purchasing an additional 1,686 shares during the last quarter. Finally, ARS Wealth Advisors LLC acquired a new position in shares of Eli Lilly and during the 4th quarter worth $1,074,000. Hedge funds and other institutional investors own 75.59% of the company’s stock.

Several research analysts have recently commented on LLY shares. Truist Securities increased their price target on shares of Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, March 22nd. Wolfe Research upgraded shares of Eli Lilly and from a “peer perform” rating to an “outperform” rating and raised their target price for the company from $147.00 to $183.00 in a research note on Thursday, December 10th. Barclays raised their target price on shares of Eli Lilly and from $190.00 to $232.00 and gave the company an “overweight” rating in a research note on Monday, February 1st. Morgan Stanley raised their target price on shares of Eli Lilly and from $190.00 to $217.00 and gave the company an “overweight” rating in a research note on Thursday, February 4th. Finally, Cowen raised their target price on shares of Eli Lilly and from $195.00 to $235.00 and gave the company an “outperform” rating in a research note on Friday, February 12th. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Eli Lilly and currently has an average rating of “Buy” and a consensus price target of $193.88.

NYSE:LLY opened at $182.32 on Thursday. The company has a 50-day moving average of $195.68 and a 200-day moving average of $171.39. The company has a market capitalization of $174.84 billion, a price-to-earnings ratio of 29.79, a PEG ratio of 1.57 and a beta of 0.37. Eli Lilly and Company has a 52 week low of $129.21 and a 52 week high of $218.00. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.06 and a current ratio of 1.36.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Thursday, January 28th. The company reported $2.75 EPS for the quarter, topping analysts’ consensus estimates of $2.35 by $0.40. The company had revenue of $7.44 billion during the quarter, compared to the consensus estimate of $7.27 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The firm’s revenue for the quarter was up 21.7% compared to the same quarter last year. During the same period last year, the firm earned $1.73 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 7.56 EPS for the current year.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction dated Monday, January 11th. The shares were sold at an average price of $185.49, for a total transaction of $40,807,800.00. Following the completion of the sale, the insider now owns 111,003,815 shares in the company, valued at approximately $20,590,097,644.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 555,284 shares of company stock valued at $106,132,302 in the last quarter. 0.09% of the stock is currently owned by corporate insiders.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading: Dual Listing

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.